Argenx Se (ARGX) Accumulated Expenses (2015 - 2024)
Argenx Se's (ARGX) quarterly Accumulated Expenses came in at $106.7 million in Q2 2024, up 51.97% YoY from $70.2 million in Q3 2023, and up 12.2% on a QoQ basis from $95.1 million in Q4 2023.
Argenx Se (ARGX) Accumulated Expenses (2015 - 2024) Analysis & Trends
Argenx Se (ARGX) has 9 years of Accumulated Expenses data on file, last reported at $106.7 million in Q2 2024.
- Quarterly Accumulated Expenses rose 51.97% year-over-year to $106.7 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $106.7 million (up 51.97% YoY) and the FY2023 annual result came in at $95.1 million, up 12.77% from the prior year.
- Accumulated Expenses climbed to $106.7 million in Q2 2024, from $95.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $106.7 million in Q2 2024 to a low of $68.9 million in Q4 2020.
- A 5-year average of $83.5 million and a median of $83.7 million in 2021 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2020 — Accumulated Expenses surged 128.13% — and 2023, when it retreated 6.7%.
- Tracing ARGX's Accumulated Expenses over 5 years: stood at $68.9 million in 2020, then climbed by 21.59% to $83.7 million in 2021, then advanced by 0.72% to $84.3 million in 2022, then climbed by 12.77% to $95.1 million in 2023, then increased by 12.2% to $106.7 million in 2024.
- The last three Accumulated Expenses figures came in at $106.7 million (Q2 2024), $95.1 million (Q4 2023), and $70.2 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 106.71 Mn |
| Dec 31, 2023 | 95.10 Mn |
| Jun 30, 2023 | 70.22 Mn |
| Dec 31, 2022 | 84.34 Mn |
| Jun 30, 2022 | 75.26 Mn |
| Dec 31, 2021 | 83.74 Mn |
| Dec 31, 2020 | 68.87 Mn |
| Dec 31, 2019 | 30.19 Mn |
| Dec 31, 2017 | 8.06 Mn |
| Dec 31, 2016 | 2.55 Mn |
| Dec 31, 2015 | 1.55 Mn |